1 recruiting, 1 withdrawn. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
Follow Brexogen Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis BxC-I17e, Placebo - Atopic Dermatitis | Phase 1 | Withdrawn | Brexogen Inc. | 2024-05-01 | 2024-08-09 | |
| A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo - Atopic Dermatitis | Phase 1 | Recruiting | Brexogen Inc. | 45 | 2023-04-18 | 2025-09-19 |
United States (1)